Related Experiment Video

Updated: Sep 17, 2025

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
09:43

Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses

Published on: March 8, 2024

1.9K

[Interaction between COVID-19 Infection and Hematological Malignancies --Review]

Zi-Heng Wang1, Jia-Yi Zhao1, Xiao-Feng Shi1

  • 1Nanjing Medical University, Nanjing 211166, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|July 4, 2025
PubMed

Insights

Hematological malignancy patients face higher COVID-19 risks. Vaccination offers benefits, and treatments like monoclonal antibodies aid recovery, but COVID-19 can delay treatment for these vulnerable individuals.

Area of Science:

  • Hematology
  • Infectious Diseases
  • Oncology

Background:

  • Patients with hematological malignancies (HM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and higher mortality.
  • COVID-19 infection can negatively impact HM patients by delaying hematopoietic recovery and compromising immunity.

Purpose of the Study:

  • To review the complex interactions between COVID-19 infection and hematological malignancies.
  • To discuss the implications for patient vulnerability, treatment strategies, and disease management.

Main Methods:

  • Literature review of studies examining COVID-19 in HM patients.
  • Analysis of vaccine efficacy, treatment outcomes, and impact on cancer therapy.

Main Results:

  • HM patients exhibit reduced vaccine response but still gain protection against infection and severe disease.
  • Monoclonal antibodies and antiviral drugs are beneficial for COVID-19 treatment in HM patients.
  • COVID-19 can necessitate adjustments in radiotherapy and chemotherapy intensity and duration for HM patients.

Conclusions:

  • Despite challenges, COVID-19 vaccination provides benefits for HM patients.
  • Integrated management strategies are crucial for addressing COVID-19 in HM patients.
  • Further research is needed to optimize care for this vulnerable population.

Keywords:
coronavirus disease 2019; hematological malignancies; COVID-19 vaccine; prognosis

More Related Videos

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays06:03

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

1.4K
An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection08:14

An In Vitro Model for Measuring Immune Responses to Malaria in the Context of HIV Co-infection

Published on: October 6, 2015

10.4K

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
504
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.2K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
1.7K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K
Hematopoiesis01:21

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.7K